Scientific Programme

Programme per day

08.30-10.00 Session 1: Update in donor management
08.30-09.15 Recruitment criteria and  retention 
M. Goldman, Canada
09.15-10.00 Donor Management : Managing blood donations from the elderly, Japanese experience
Y. Tani, Japan
10.00-10.30 Coffee break
10.30-11.00 Session 2:  Thailand update
11.00-11.30 National Blood Centre, the Thai Red Cross Society: Strategy on self-sufficiency 
U. Charoonrungrit , Thailand
11.00-11.40 Session 3: Immunohaematology
11.00-11.40 Solving challenging cases in Immunohaematology: from serological to molecular tools
YW Liew, Australia
11.40-12.30 Lunch
14.00-16.00 Royal Opening
08.30-09.00 Opening Ceremony
09.00-10.30 Plenary: New insights in immunohaematology
09.00-09.30 Advances in genomics on the study of rare blood groups
J. Storry, Sweden
09.30-10.00 Red cell genotyping in Thailand: Trends for blood transfusion in the Asian population
O. Nathalang, Thailand
10.00-10.30 Kodecytes: modifying the sur-face of red cells
S. Henry, New Zealand
10.30-11.00 Coffee break
11.00-12.30 Scientific: Apheresis
11.00-11.30 Current challenges in therapeutic apheresis
T. Triyono, Indonesia
11.30-12.30 4 x 15 minutes for selected abstracts
11.00-12.30 Academy: Thalassaemia
11.00-11.30 Molecular basis of thalassemia and haemoglobinopathies
S. Fucharoen, Thailand
11.30-12.00 Carrier screening and prenatal diagnosis of haemoglobinopathies
H. Ibrahim, Malaysia
12.00-12.30 Current standards and latest developments in the treatment of thalassemia
N. Taewtrakul, Thailand
12.30-14.00 Lunch
14.00-15.30 Scientific: Best young investigators abstracts
14.00-15.30 6 x 15 minutes for selected abstracts
14.00-15.30 Scientific: TTI and emerging diseases
14.00-14.30 Hepatitis B and C epidemiology and blood transfusion in Indonesia
D. H. Muljono, Indonesia
14.30-15.00 Malaria: human genetic variants
V. Viprakasit, Thailand
15.00-15.30 2 x 15 minutes for selected abstracts
15.30-16.00 Coffee Break
16.00-17.30 Scientific: Donor Management
16.00-16.30 Iron deficinecy and blood donation: What to do
M. Goldman, Canada
16.30-17.00 2 x 15 minutes for selected abstracts
17.00-17.30 TBA
16.00-17.30 Academy: Quality Management
16.00-16.30 Education and training techniques to implement regulatory requirements
N. Ritchie, Indonesia
16.30-17.00 From job description to qualification and competence assessment
M. Pyke, Australia
17.00-17.30 Good practice of change control for the validation of assays and test systems
S. Lam, Singapore
08.30-10.00 Plenary: Perspectives on Hepatitis, Zika and Dengue
08.30-09.00 Epidemiology and elimination of hepatitis by the year 2030
Y. Poovorawan, Thailand
09.00-09.30 New insights in Zika virus infection
D. Musso, French Polynesia
09.30-10.00 Asia Pacific Blood Network (APBN) Dengue White Paper; Dengue and the blood supply, 2019 update
V. Hoad, Australia



10.30-12.00 Scientific: Pediatric and Perinatal transfusion
10.30-11.00 Prenatal support and Intrauterine transfusion
G. Clarke, Canada
11.00-11.30 Haemolytic disease of the fetus and newborn; new perspectives
M. de Haas, Netherlands
11.30-12.00 2 x 15 minutes for selected abstracts
10.30-12.00 Academy: Immunohaematology MNS
10.30-11.00 Molecular typing for bood group antigens: an overview
J. Li, China
11.00-11.30 Overview and updates on MNS antigen system
G. Lopez, Australia
11.30-12.00 Rare donor program: how to find and provide rare blood
Y. Tani, Japan
13.30-15.00 Scientific: Immunohaematology and Molecular Testing
13.30-14.00 Molecular immunohaematology for transfused thalassaemic patients
P. Watanaboonyongcharoen, Thailand
14.00-15.00 4 x 15 minutes for selected abstracts
13.30-15.00 Academy: Haemovigilance 
13.30-13.50 Overview and update on international activities
N. Goto, Japan
13.50-14.10 Hemovigilance country report: Thailand
P. Rojnuckarin, Thailand
14.10-14.30 Setting up a haemovigilance program in Mongolia
N. Erdenebayar, Mongolia
14.30-14.50 Haemovigilance in Korea: what has been achieved?
J. Hyun, Korea
14.50-15.00 Discussion
15.30-17.00 Scientific: Blood cell immunology
15.30-16.00 Human platelet antigen frequencies and antibodies in SE Asia
N. Tsuno, Japan
16.00-16.30 Human blood group alloantiboides and their consequences
V. Nadarajan, Malaysia
16.30-17.00 TBA
15.30-17.00 Academy: Patient Blood Management
15.30-16.00 Concept of PBM, how to start
S. Allard, UK
16.00-16.30 Experience in setting up a PBM program: Korea
T. Um, Korea
16.30-17.00 Singapore's perspective on Patient Blood Management
A. Ang, Singapore
17.00-18.00 Poster session
19.30- Congress party
08.30-10.00 Plenary: An update on stem cells and cellular therapy
08.30-09.00 The challenge of stem cell tourism
D. Sipp, Japan
09.00-09.30 Cell and gene therapy: Experiences in Thailand
S. Hongeng, Thailand
09.30-10.00 CAR-T treatment for B-cell ALL: experience from Lu Daopei Hospital in China
P. Lu, China
  Coffee Break
10.30-12.00 Scientific: Haemoglobinopathies
10.30-11.00 Managing thalassemia in Indonesia: A work in progress
P. Amalia, Indonesia
11.00-12.00 4 x 15 minute slots for selected abstracts
10.30-12.00 Academy: TTI
10.30-11.00 Risks of transmission of blood borne diseases in the donor population
M. Janssen, The Netherlands
11.00-11.20 What is the I TRY IT program, and what do you need to know about it?
B. Custer, USA
11.20-11.35 My ITRY It experience
E. Nnakelu, Nigeria
11.35-11.50 RHD polymorphisms among blood donors in Morocco
H. El Housse, Morocco
11.50-12.00 Discussion
13.30-15.00 Scientific: Adverse events and haemovigilance
13.30-14.00 Models of TACO/TRALI pathophysiology: what have they taught us
R. Kapur, Netherlands
14.00-15.00 4 x 15 minute slots for selected abstracts
13.30-15.00 Academy: Ethics
13.30-14.00 Balancing safety and sufficiency
P. Flanagan, New Zealand
14.00-14.30 Making donor safety a priority
M. Goldman, Canada
14.30-15.00 Discussion
15.30-17.00 Plenary: The hidden world of platelets and megakaryocytes
15.30-16.00 Platelet immunology from the inside out
J. Semple, Sweden
16.00-16.30 Platelets in thrombo-inflammation: how they get there & how to stop them
J. Hamilton, Australia
16.30-17.00 Novel Mechanisms by which Megakaryocytes Respond to and Propagate Inflammation
K. Machlus, US
  Closing Ceremony